PAncreatic Cancer therapeutic discovery using Monoclonal ANtibodies

The PACMAN project aims to develop a novel therapeutic approach for treating pancreatic ductal adenocarcinomas (PDAC), one of the deadliest cancers with limited therapeutic options.

The project focuses on targeting an overexpressed cell surface protein in PDAC implicated in tumor proliferation, invasion and migration by driving carcinogenic signaling.

This study aims to investigate the ability of a highly specific monoclonal antibody targeting this protein to treat PDAC.

By studying the therapeutic efficacy and unravelling associated biomarkers of treatment response in patient-derived PDAC models, the PACMAN program will provide preclinical proof of concept to treat PDAC with a novel class of monoclonal antibodies.

Based on a robust patient-derived data package, this innovative approach provides the perspective for a first-in-class therapy for PDAC, addressing a critical unmet medical need and offering new hope for patients with this aggressive cancer.